Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H24ClN3O2 |
| Molecular Weight | 349.855 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=C(Cl)C=C(C(=O)N[C@@H]2C[N@@]3CC[C@H]2CC3)C(OCC4CC4)=C1
InChI
InChIKey=DBQMQBCSKXTCIJ-MRXNPFEDSA-N
InChI=1S/C18H24ClN3O2/c19-14-7-13(17(8-15(14)20)24-10-11-1-2-11)18(23)21-16-9-22-5-3-12(16)4-6-22/h7-8,11-12,16H,1-6,9-10,20H2,(H,21,23)/t16-/m1/s1
Pancopride (LAS 30451) is a 5-hydroxytryptamine 3 receptor antagonist and was developed against cytotoxic drug-induced emesis. Pancopride was studied in clinical trials in patients treated with highly emetogenic chemotherapy. It was found a combination of Pancopride with dexamethasone was the most effective against chemotherapy-induced vomiting. However, information about the further development of this drug is not available.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis. | 1992 Nov 10 |
|
| LAS 30451: a novel 5-HT3 antagonist. | 1993 |
|
| Single dose pharmacokinetics and tolerance of pancopride in healthy volunteers. | 1995 Feb |
|
| Prevention of highly emetogenic chemotherapy-induced vomiting: a double blind, randomized crossover study to compare pancopride (LAS 30451) and pancopride plus dexamethasone. | 1995 Nov-Dec |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
72710794
Created by
admin on Sat Dec 16 11:02:01 GMT 2023 , Edited by admin on Sat Dec 16 11:02:01 GMT 2023
|
PRIMARY | |||
|
2V4M6ABH0V
Created by
admin on Sat Dec 16 11:02:01 GMT 2023 , Edited by admin on Sat Dec 16 11:02:01 GMT 2023
|
PRIMARY | |||
|
137765-22-1
Created by
admin on Sat Dec 16 11:02:01 GMT 2023 , Edited by admin on Sat Dec 16 11:02:01 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
